Presentation is loading. Please wait.

Presentation is loading. Please wait.

Thoracic Surgery Innovations. Innovations VATS LVRS Chemotherapy Radiotherapy PET Small Cell N2 Stents & Lasers Stapler In Oesophagogastrectomy Epidural.

Similar presentations


Presentation on theme: "Thoracic Surgery Innovations. Innovations VATS LVRS Chemotherapy Radiotherapy PET Small Cell N2 Stents & Lasers Stapler In Oesophagogastrectomy Epidural."— Presentation transcript:

1 Thoracic Surgery Innovations

2 Innovations VATS LVRS Chemotherapy Radiotherapy PET Small Cell N2 Stents & Lasers Stapler In Oesophagogastrectomy Epidural SVC stents

3 VATS Sympathectomy Pleurectomy Lobectomy Biopsy –mass –lung

4

5

6 Pneumothorax

7 Pleurectomy VAT Muscle sparing Mini Full Thoracotomy

8 VAT Lobectomy

9 Biopsy Lung / Pleura

10

11 LVRS

12

13

14 Criteria Dyspnoeic on daily activities Age < 75 No bullae > 5cm Generalised emphysema with regional heterogeneity TLC > 125% FEV1 < 30 % PaCO2 40 mmHg on air No CAD or Pulmonary hypertension Steroid < 15 mg/day

15 LVRS Unilateral / Bilateral Thoracotomy / Sternotomy / VAT Role of Physio

16

17 Chemotherapy and Radiotherapy PreoperativeNeoadjuvant Operative PostoperativeAdjuvant

18 Chemotherapy Numerous agents Adjuvant –Stage II (T2N0) –? Role in N2 disease –All oat cell Neoadjuvant Stage IIIA (N2) –If respond are resected –No residual tumour at surgery means prolonged survival –Experimental

19 Radiotherapy External beam external rays –Single / multiple beam / Fraction No Brachy local ie intra bronchial –Interstitialdirectly into tumour –Intra cavityin bronchus Adjuvant Postoperative Neoadjuvant Preoperative

20 Radiotherapy Primary treatment –Stage 1 and 2 –Refuse or unfit for surgery –Failure 30 % stage 1 (T1N0), 70% stage 2 (T2N0) –5 year survival 5 to 40% Adjuvant for N1 / N2 –Reduces rate local recurrence –Survival unchanged –? Role in +Ve resection margins

21 Radiotherapy Neoadjuvant –T3 Pancoast prior to surgery Palliative –Symptomatic relief –Pain, haemoptysis, bronchial, SVC obstruction –Bone met pain Brachytherapy –Local application high local dose

22 Chemotherapy and Radiotherapy Adjuvant Neoadjuvant Sequential / concurrent / alternating Good performance status Not standard practice May increase risk surgery

23 PET 2-(fluorine-18) fluo-2-deoxy-D-glucose (18- FDG) 18-FDG competes with glucose for facilitated transport into tumour cells and also competes with glucose for phosphorylation by hexokinase Positive and negative predictive power

24

25

26 Small Cell Lung Cancer

27 Small Cell All need : Mediasteinoscopy CT head Bone scan

28 Pre operative N2 Young patients Pre op chemo downstage No evidence

29 Stents & Lasers Malignant terminal conditions that are inoperable Benign inoperable conditions

30 Tracheal obstruction-malignant - Pre and post Nd:Yag laser

31 Left main bronchus extensive squamous cell carcinoma Metal stent in left main

32 Stapler In Oesophagogastrectomy

33 Epidural Pain Poor PFTs Cardiac history Contraindications –Low risk –On anticoagulants –Consent –Anatomical –Infective

34

35

36 SVC Stents

37

38 Any Questions ?

39 Next Week 2nd March Inotropes ITU seminar room


Download ppt "Thoracic Surgery Innovations. Innovations VATS LVRS Chemotherapy Radiotherapy PET Small Cell N2 Stents & Lasers Stapler In Oesophagogastrectomy Epidural."

Similar presentations


Ads by Google